DTM™ SCS endurance therapy Spinal cord stimulation

DTM™ SCS endurance therapy is a spinal cord stimulation (SCS) therapy available to treat patients with chronic, intractable pain.

Access clinical posters

DTM™ SCS endurance
therapy overview

Building on the foundation of Differential Target
Multiplexed™ (DTM) spinal cord stimulation (SCS),
DTM™ SCS endurance therapy is an energy modified
differential target multiplexed therapy offering
meaningful pain relief, satisfaction, and quality of
life improvements.1 This enables you to personalize
care for those seeking recharge-free longevity or
less frequent recharging.

Inspired by science

DTM™ SCS therapy options are inspired by decades of basic science research and preclinical understanding. In a preclinical study, the DTM™ programming (DTMP) derivatives modulated neuro-inflammatory processes more than low-rate SCS.*2

Clinical results show meaningful pain relief

Study objectives

DTM™ SCS endurance therapy study is a prospective, multicenter, single-arm study designed to evaluate the long-term efficacy and energy use of DTM™ SCS endurance therapy.1

Primary objective: To evaluate the effectiveness of DTM™ SCS endurance therapy in reducing overall pain intensity at 3-months follow up.

Secondary objectives with follow up to 12-months:

  • Characterize changes in pain intensity for overall, back, and leg pain
  • Characterize programming parameters associated with energy use
  • Characterize changes in functional disability as measured by Oswestry disability index (ODI)
  • Characterize subject satisfaction
  • Characterize therapy safety data

12-Month Outcomes

Meaningful
pain relief

4.6

cm reduction in VAS for overall pain
from baseline to 12 months1

Mean overall VAS

Overall pain

Note: *Subjects were excluded from analysis at 6-Months due to programming changes from DTMTM SCS endurance therapy (N=1) and due to study exit (N=1). **Subjects were excluded from analysis at 12-Months due to programming changes from DTMTM SCS endurance therapy (N=2) and due to study exit (N=1)​

Meaningful quality of
life improvements

76%

of patients improved in degree of disability
at 12-month follow up1

Meaning ODI scores

Quality of life graph

Therapy satisfaction

86%

of patients were
satisfied with therapy1

Long lasting

5½-7½

years of recharge-free longevity
estimated using actual
12-month programming data3

Save time

5 minutes

estimated daily rapid recharge
or recharge less frequently
(1 hour every 12 days)3

Superior
pain relief

DTM™ SCS offers proven pain relief backed by data on Intellis™ SCS. Learn about the therapy.

See DTM™ SCS

Vanta™ SCS neurostimulator

High performance and recharge free. Experience DTM™ SCS endurance therapy on Vanta™.
 

Learn more

Intellis™ SCS neurostimulator 

Rapid recharge available with DTM™ SCS or DTM™ SCS endurance therapy. 
 

Discover Intellis™ SCS

*Note: Data obtained from animal studies should not be extrapolated to clinical/human results.

1

Provenzano, Peacock, Fishman, et al. A prospective multi-center study of a reduced-energy DTM™ stimulation derivative: Long-term outcomes in therapy naïve patients. Poster presented at: American Society of Regional Anesthesia and Pain Medicine (ASRA) Annual Pain Medicine Meeting; Nov. 17–19, 2022; Orlando, FL, USA.

2

Cedeno D, Vallejo R, Platt D, et al. Differential target multiplexed SCS using reduced energy parameters in an animal model of neuropathic pain. Poster presented at: American Society of Pain and Neuroscience (ASPN) annual meeting. July 22&nash;25, 2021.

3

Provenzano, Amirdelfan, Grewal, et al. Modeling energy demands of a reduced-energy derivative of DTM™ stimulation on rechargeable and recharge-free SCS systems. Poster presented at: American Society of Regional Anesthesia and Pain Medicine (ASRA) Annual Pain Medicine Meeting; Nov. 17–19, 2022; Orlando, FL, USA.